Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

44%

8 trials in Phase 3/4

Results Transparency

50%

7 of 14 completed with results

Key Signals

7 with results100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (1)
P 1 (2)
P 2 (4)
P 3 (6)
P 4 (2)

Trial Status

Completed14
Recruiting3
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05355818Phase 3CompletedPrimary

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

NCT02664805Phase 2CompletedPrimary

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

NCT05026554RecruitingPrimary

Characterization of Chronic Hand Eczema

NCT05994976Recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

NCT06283550Phase 2CompletedPrimary

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

NCT06004050Phase 3CompletedPrimary

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

NCT05259722Phase 3CompletedPrimary

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

NCT04872101Phase 3CompletedPrimary

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)

NCT04949841Phase 3CompletedPrimary

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

NCT04871711Phase 3CompletedPrimary

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema

NCT05486117Phase 1CompletedPrimary

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

NCT03683719Phase 2CompletedPrimary

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

NCT03861455Phase 2CompletedPrimary

Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids

NCT04378569Phase 1CompletedPrimary

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT05545215WithdrawnPrimary

Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema

NCT05682859Phase 4RecruitingPrimary

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

NCT03246776Phase 4CompletedPrimary

Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan

NCT01482663Not ApplicableCompletedPrimary

Chronic Hand Eczema - Self-management and Prognosis

Showing all 18 trials

Research Network

Activity Timeline